

***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

1-23. (cancelled).

24. (currently amended) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a r $\Delta$ Nt polypeptide, wherein said cells comprise a polynucleotide having a nucleotide sequence ~~at least 95% identical to a sequence~~ selected from the group consisting of:

(i) a nucleotide sequence from about position 1 to about position 1320 in SEQ ID NO:1, wherein the extracellular amino-terminal ligand binding domain is deleted;

(ii) a nucleotide sequence from about position 4 to about position 1320 in SEQ ID NO:1, wherein the extracellular amino-terminal ligand binding domain is deleted;

(iii) a nucleotide sequence from about position 67 to about position 1320 in SEQ ID NO:1, wherein the extracellular amino-terminal ligand binding domain is deleted;

(iv) a nucleotide sequence encoding the r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136, wherein the extracellular amino-terminal ligand binding domain is deleted; and

(v) a nucleotide sequence encoding the mature r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136, wherein the extracellular amino-terminal ligand binding domain is deleted;

wherein said polypeptide increases intracellular cAMP levels when activated by PTH or PTH-related peptide and wherein said extracellular amino-terminal ligand binding domain has an amino acid sequence from about residue 26 to about residue 181 in wild-type PTH receptor;

(b) measuring cAMP accumulation in said cells; and

(c) determining whether said test compound is an agonist or an antagonist of PTH receptor activity;

wherein an agonist is identified as a compound that increases cAMP accumulation and an antagonist prevents cAMP accumulation.

25. (previously presented) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a r $\Delta$ Nt polypeptide having an amino acid sequence selected from the group consisting of:

(i) the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2;

(ii) the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2;

(iii) the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2;

(iv) the amino acid sequence of the r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136; and

(v) the amino acid sequence of the mature r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136;

wherein said polypeptide comprises a deletion of the extracellular amino-terminal ligand binding domain of a PTH-1 receptor, said extracellular amino-terminal ligand binding domain having an amino acid sequence from about residue 26 to about residue 181 in wild-type PTH receptor;

(b) measuring cAMP accumulation in said cells; and

(c) determining whether said test compound is an agonist or an antagonist of PTH receptor activity;

wherein an agonist is identified as a compound that increases cAMP accumulation and an antagonist prevents cAMP accumulation.

26. (previously presented) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a r $\Delta$ Nt polypeptide, wherein said cells comprise a polynucleotide having a nucleotide sequence selected from the group consisting of:

- (i) a nucleotide sequence encoding the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2;
- (ii) a nucleotide sequence encoding the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2;
- (iii) a nucleotide sequence encoding the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2;
- (iv) a nucleotide sequence encoding the rΔNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136; and
- (v) a nucleotide sequence encoding of the mature rΔNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136;

wherein said polypeptide comprises a deletion of the extracellular amino-terminal ligand binding domain of a PTH-1 receptor, said extracellular amino-terminal ligand binding domain having an amino acid sequence from about residue 26 to about residue 181 in wild-type PTH receptor;

- (b) measuring the biological response of cAMP accumulation in said cells; and
- (c) determining whether said test compound is an agonist or an antagonist of PTH receptor activity;

wherein an agonist is identified as a compound that increases cAMP accumulation and an antagonist prevents cAMP accumulation.

27. (currently amended) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

- (a) providing an iodinated test compound;
- (b) contacting cells with said iodinated test compound wherein said cells express a r $\Delta$ Nt polypeptide, wherein said cells comprise a polynucleotide having a nucleotide sequence ~~at least 95% identical to a sequence~~ selected from the group consisting of:
  - (i) a nucleotide sequence from about position 1 to about position 1320 in SEQ ID NO:1, wherein the extracellular amino-terminal ligand binding domain is deleted;
  - (ii) a nucleotide sequence from about position 4 to about position 1320 in SEQ ID NO:1, wherein the extracellular amino-terminal ligand binding domain is deleted;
  - (iii) a nucleotide sequence from about position 67 to about position 1320 in SEQ ID NO:1, wherein the extracellular amino-terminal ligand binding domain is deleted;
  - (iv) a nucleotide sequence encoding the r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136, wherein the extracellular amino-terminal ligand binding domain is deleted; and
  - (v) a nucleotide sequence encoding the mature r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136, wherein the extracellular amino-terminal ligand binding domain is deleted;

wherein said polypeptide increases intracellular cAMP levels when activated by PTH or PTH-related peptide and wherein said extracellular amino-terminal ligand binding domain has an amino acid sequence from about residue 26 to about residue 181 in wild-type PTH receptor; and

(b) determining whether said iodinated test compound competitively binds to said rΔNt polypeptide;

wherein an agonist is identified as a compound that increases cAMP accumulation and an antagonist prevents cAMP accumulation.

28. (currently amended) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) providing an iodinated test compound;

(b) contacting cells with said iodinated test compound wherein said cells express a rΔNt polypeptide having an amino acid sequence ~~at least 95% identical to a sequence~~ selected from the group consisting of:

(i) the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2, wherein the extracellular amino-terminal ligand binding domain is deleted;

(ii) the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2, wherein the extracellular amino-terminal ligand binding domain is deleted;

(iii) the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2, wherein the extracellular amino-terminal ligand binding domain is deleted;

(iv) the amino acid sequence of the r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136, wherein the extracellular amino-terminal ligand binding domain is deleted; and

(v) the amino acid sequence of the mature r $\Delta$ Nt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136, wherein the extracellular amino-terminal ligand binding domain is deleted;

wherein said polypeptide increases intracellular cAMP levels when activated by PTH or PTH-related peptide and wherein said extracellular amino-terminal ligand binding domain has an amino acid sequence from about residue 26 to about residue 181 in wild-type PTH receptor; and

(b) determining whether said iodinated test compound competitively binds to said r $\Delta$ Nt polypeptide;  
wherein an agonist is identified as a compound that increases cAMP accumulation and an antagonist prevents cAMP accumulation.

29. (new) The method of claim 24, wherein said cells comprise a polynucleotide having a nucleotide sequence from about position 1 to about position 1320 in SEQ ID NO:1.

30. (new) The method of claim 24, wherein said agonist is a peptide.

31. (new) The method of claim 24, wherein said antagonist is a peptide.
32. (new) The method of claim 25, wherein said cells express a rΔNt polypeptide having an amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2.
33. (new) The method of claim 25, wherein said agonist is a peptide.
34. (new) The method of claim 25, wherein said antagonist is a peptide.
35. (new) The method of claim 26, wherein said cells comprise a polynucleotide which encodes a polypeptide having the amino acid sequence from about 1 to about position 435 in SEQ ID NO:2.
36. (new) The method of claim 26, wherein said agonist is a peptide.
37. (new) The method of claim 26, wherein said antagonist is a peptide.
38. (new) The method of claim 27, wherein said cells comprise a polynucleotide having a nucleotide sequence from about position 1 to about position 1320 in SEQ ID NO:1.



39. (new) The method of claim 27, wherein said agonist is a peptide.
40. (new) The method of claim 27, wherein said antagonist is a peptide.
41. (new) The method of claim 28 wherein said cells express a rΔNt polypeptide having an amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2.
42. (new) The method of claim 28, wherein said agonist is a peptide.
43. (new) The method of claim 28, wherein said antagonist is a peptide.